Lylia Chachoua

Economics, Econometrics and Finance · Social Sciences

4h-index167citations33works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmaceutical Economics and Policy(20), Health Systems, Economic Evaluations, Quality of Life(18), Innovation Policy and R&D(5), Pharmaceutical industry and healthcare(3), Economic and Financial Impacts of Cancer(3)

Publications33 total

HTA114 Diverging Health Technology Assessment Outcomes Between SMC and HAS: A Focus on the Role of Indirect Treatment Comparisons
Value in Health·2025
HPR138 Market Access Challenges for Oncology Combination Therapies in Europe: A Review of Regulatory Approvals HTA Outcomes and Pricing Dynamics
Value in Health·2025
HTA245 Navigating Joint Clinical Assessment in Europe: Strategic Roadmap and Recommendations for Health Technology Developers
Value in Health·2025
HTA19 The Impact of Meeting Orphan Criteria on Reimbursement Decisions and ICERs in Scotland
Value in Health·2025
HTA20 Drivers of High ICERs in SMC Appraisals
Value in Health·2025
MT20 Innovations in Digital Therapeutics: An Analysis of Clinical Trials and Regulatory Status in Europe and the US
Value in Health·2024
HTA279 Retrospective Analysis of the French Early Access Experience Following the 2021 Reform
Value in Health·2023
HTA353 Analysis of the Impact of Early Access Decisions on Pricing and Reimbursement Decisions in France
Value in Health·2023Open Access
Drivers of Patient and Caregiver Preferences for Growth Hormone Deficiency Treatments in France: A Discrete Choice Experiment
Hormone Research in Paediatrics·2023· 1 cited
Supplementary Material for: Drivers of patient and caregiver preferences for growth hormone deficiency treatments in France: a discrete choice experiment
Figshare·2023Open Access
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies
Advances in Therapy·2022· 18 citedOpen Access
Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
Frontiers in Medicine·2020· 31 citedOpen Access
Managed Entry Agreements: Policy Analysis From the European Perspective
Value in Health·2020· 100 cited
PNS365 THE ADDED VALUE OF USE OF PATIENT PREFERENCE STUDIES IN POLICY DECISION-MAKING: A LITERATURE REVIEW
Value in Health·2019Open Access
PND5 OVERCOMING MARKET ACCESS AND COMMERCIALIZATION CHALLENGES IN GENE THERAPIES FOR RARE CNS DISEASES: GENE THERAPY CLINICAL TRIALS FOR RARE CNS DISEASES LANDSCAPE
Value in Health·2019Open Access
The diversity in regenerative medicines regulations in Europe, USA and Japan
Cell and Gene Therapy Insights·2019· 2 cited
Why “American Patients First” is likely to raise drug prices outside of the United States
Journal of Market Access & Health Policy·2019· 1 citedOpen Access
President Trump’s prescription to reduce drug prices: from the campaign trail to American Patients First
Journal of Market Access & Health Policy·2019· 7 citedOpen Access
Heterogeneous Recommendations for Oncology Products Among Different HTA Systems: A Comparative Assessment
Recent results in cancer research/Recent Results in Cancer Research·2018· 3 cited
PSY59 - ORPHAN DRUGS PRICES COMPARISON IN MIDDLE EAST NORTH AFRICA (MENA) REGION
Value in Health·2018· 1 cited
page 1 of 2Next →

Frequent Co-authors

Mondher Toumi(25), Monique Dabbous(16), E. Hanna(16), Claude Dussart(8), Leila Achour(8), C. François(7), Samuel Aballéa(7), Ines Abdelghani(5), Aleksandra Caban(3), Mondher Toumi(3), Meriem Fadhel(3), Steven Simoens(2), Béatrice Demaret(2), Robin Henocque(2), Lara Salvi(2), Philippe Touraine(2), BN Borissov(2), Marta Wilk(2), Tingting Qiu(2), Hend Jedidi(2)